{
    "nctId": "NCT00898508",
    "briefTitle": "Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease",
    "officialTitle": "Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 563,
    "primaryOutcomeMeasure": "Establishment of a specimen bank",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Biopsy-confirmed diagnosis of one of the following:\n\n  * Stage I-IV infiltrating ductal or infiltrating lobular carcinoma\n\n    * Patients with early-stage disease must not have started systemic treatment; if no systemic treatment is planned, patients must be either preoperative or \u2264 120 days since definitive breast surgery\n    * Patients with locally advanced disease must be scheduled for neoadjuvant chemotherapy prior to initiation of systemic treatment\n  * Ductal carcinoma in situ\n  * Lobular carcinoma in situ\n  * Benign breast disease\n\n    * Proliferative or non-proliferative\n    * With or without atypia\n\nPATIENT CHARACTERISTICS:\n\n* Karnofsky performance status 50-100%\n* Not pregnant\n* No prior invasive cancer diagnosis within the past 5 years except for squamous cell or basal cell carcinoma of the skin\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior systemic therapy (chemotherapy or hormonal therapy) for patients with stage I-III disease",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}